Discontinuation report ACT ETIDROCAL
| Report ID | 76486 |
| Drug Identification Number | 02263866 |
| Brand name | ACT ETIDROCAL |
| Common or Proper name | ETIDROCAL |
| Company Name | TEVA CANADA LIMITED |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | ETIDRONATE DISODIUM CALCIUM |
| Strength(s) | 400MG 500MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 90 |
| ATC code | M05BB |
| ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2019-02-28 |
| Actual discontinuation date | 2019-02-28 |
| Remaining supply date | 2018-05-01 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2019-03-01 | English | Compare |
| v2 | 2019-02-21 | French | Compare |
| v1 | 2019-02-21 | English | Compare |
Showing 1 to 3 of 3